Sinovac coronavirus vaccine offered by Chinese city for emergency use costs $60

Sinovac coronavirus vaccine offered by Chinese city for emergency use costs $60

The US Food and Drug Administration has said it wants at least two months of safety data before authorizing emergency use of any experimental coronavirus vaccine.

The registered vaccine, EpiVacCorona, was developed at a research centre in the Siberian city Novosibirsk, said Putin.

"I know there is a great deal of confusion regarding exactly what it will take to ensure its development and approval, and given the critical public health considerations and the importance of transparency, I would like to provide greater clarity around the development timelines for Pfizer's and our partner BioNTech's COVID-19 vaccine", Bourla said.

During a televised meeting with government officials on Wednesday, Russian President Vladimir Putin announced that the country has registered the second Covid-19 vaccine.

TASS news agency reported that the human trial of the new vaccine candidate, EpiVacCorona will begin in November or December and it will involve around 30,000 participants. "This means we may know whether or not our vaccine is effective by the end of October", he said.

Pfizer Inc expects to provide safety data and file for authorization of the Covid-19 vaccine it is developing with German partner BioNTech in late November, delaying any clarity on the vaccine until after the November 3 U.S. presidential election.

In an open letter published on the company's web site, Pfizer (PFE) chairman and CEO Albert Bourla said that there must be certainty that the vaccine is safe and will satisfy regulators' standards.

Musk Claims Tesla Model S Price Will Be Lowered To $69,420
The Model S makes up only around 5% of Tesla's unit volume, according to a Credit Suisse analyst note on Wednesday. Tesla CEO and resident meme maker Elon Musk just tweeted that the Model S sedan will soon be priced at $69,420.

Bourla estimated that Pfizer's 44,000-person study would reach that milestone in the third week of November.

China National Pharmaceutical Group (Sinopharm) said in August that a vaccine candidate developed by a unit may cost no more than 1,000 yuan (RM 618) for two shots. If the vaccine is looking significantly better than the placebo, the companies can apply for emergency use, and the study may be halted or continue to its intended conclusion.

A BioNTech spokesperson confirmed the time frame for the potential EUA application to the FDA.

"We are operating at the speed of science", he wrote in a letter posted to the company's website.

This comes at a time when COVID-19 cases in the USA are climbing slightly, but the coronavirus deaths are relatively level this month.

However, whether the shot can safely protect people from the Covid-19 disease that has killed more than one million people worldwide will only become clear when final Phase III trials - which are ongoing outside China - are complete.

The first batch of Russia's Sputnik-V vaccine against the novel coronavirus was delivered to Venezuela in early October, and 2,000 volunteers have been selected to participate in the trials.

Related Articles